Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity

Gabizon, 1992, Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes, Cancer Res., 52, 891 Northfelt, 1996, Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma, J. Clin. Pharmacol., 36, 55, 10.1002/j.1552-4604.1996.tb04152.x Gill, 1996, Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma, J. Clin. Oncol., 14, 2353, 10.1200/JCO.1996.14.8.2353 Casazza, 1980, Effects of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor acitivity and toxicity of daunorubicin and doxorubicin, 403 Arcamone, 1976, Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers, Cancer Treat. Rep., 60, 829 Ames, 1992, Selected pharmacologic characteristics of idarubicin and idarubicinol, Leukemia, 6, 70 Casazza, 1979, Experimental evaluation of anthracycline analogs, Cancer Treat. Rep., 63, 835 Willmore, 2002, Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells, Biochem. Pharmacol., 63, 1807, 10.1016/S0006-2952(02)00920-6 Limonta, 1990, Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells, Cancer Chemother. Pharmacol., 26, 340, 10.1007/BF02897289 Ross, 1995, Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance, Biochem. Pharmacol., 50, 1673, 10.1016/0006-2952(95)02069-1 Kuffel, 1992, Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture, Cancer Chemother. Pharmacol., 30, 51, 10.1007/BF00686485 Roovers, 1999, Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines, Leuk. Res., 23, 539, 10.1016/S0145-2126(99)00041-7 Testi, 1995, Evaluation of resistance index of several anticancer agents on parental and resistant P-388 cell lines, Leuk. Res., 19, 257, 10.1016/0145-2126(94)00157-6 Berman, 1992, Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells, Blood, 79, 3267, 10.1182/blood.V79.12.3267.3267 Wiernik, 1992, Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia, Blood, 79, 313, 10.1182/blood.V79.2.313.313 Berman, 1991, Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia, Blood, 77, 1666, 10.1182/blood.V77.8.1666.1666 Martoni, 1990, Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer, Oncology, 47, 427, 10.1159/000226863 Broggini, 1984, Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors, Cancer Treat. Rep., 68, 739 Penco, 1983, Synthesis, antitumor activity, and cardiac toxicity of new 4-demethoxyanthracyclines, Cancer Treat. Rep., 67, 665 Gallois, 1996, The overall partitioning of anthracyclines into phosphatidyl-containing model membranes depends neither on the drug charge nor the presence of anionic phospholipids, Eur. J. Biochem., 241, 879, 10.1111/j.1432-1033.1996.00879.x Mulder, 1995, The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity, Biochem. Pharmacol., 50, 967, 10.1016/0006-2952(95)00221-K Dos Santos, 2002, Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes, Biochim. Biophys. Acta, 1561, 188, 10.1016/S0005-2736(02)00345-0 Olson, 1979, Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes, Biochim. Biophys. Acta, 557, 9, 10.1016/0005-2736(79)90085-3 Derksen, 1987, Processing of different liposome markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages, Biochim. Biophys. Acta, 931, 33, 10.1016/0167-4889(87)90047-4 Mayer, 1986, Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient, Biochim. Biophys. Acta, 857, 123, 10.1016/0005-2736(86)90105-7 Redelmeier, 1989, Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients, Biophys. J., 56, 385, 10.1016/S0006-3495(89)82684-0 Almgren, 1996, Cryo-transmission electron microscopy of thin vitrified samples, Curr. Opin. Colloid Interface Sci., 1, 270, 10.1016/S1359-0294(96)80015-X Bally, 1990, Liposomes with entrapped doxorubicin exhibit extended blood residence times, Biochim. Biophys. Acta, 1023, 133, 10.1016/0005-2736(90)90018-J Mosmann, 1983, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods, 65, 55, 10.1016/0022-1759(83)90303-4 Alley, 1988, Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay, Cancer Res., 48, 589 Mui, 1993, Osmotic properties of large unilamellar vesicles prepared by extrusion, Biophys. J., 64, 443, 10.1016/S0006-3495(93)81385-7 Shabbits, 2002, P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs, Mol. Cancer Ther., 1, 205 Mayer, 1989, Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice, Cancer Res., 49, 5922 Mayer, 1993, Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia, Cancer Chemother. Pharmacol., 33, 17, 10.1007/BF00686017 Webb, 1995, Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models, Br. J. Cancer, 72, 896, 10.1038/bjc.1995.430 Lim, 2000, Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors, J. Pharmacol. Exp. Ther., 292, 337 Hashizaki, 2003, Effects of poly(ethylene glycol) (PEG) chain length of PEG-lipid on the permeability of liposomal bilayer membranes, Chem. Pharm. Bull. (Tokyo), 51, 815, 10.1248/cpb.51.815 Nicholas, 2000, Effect of grafted polyethylene glycol (PEG) on the size, encapsulation efficiency and permeability of vesicles, Biochim. Biophys. Acta, 1463, 167, 10.1016/S0005-2736(99)00192-3 Edwards, 1997, Effect of polyethyleneglycol-phospholipids on aggregate structure in preparations of small unilamellar liposomes, Biophys. J., 73, 258, 10.1016/S0006-3495(97)78066-4 Allen, 2002, Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol), Biosci. Rep., 22, 225, 10.1023/A:1020186505848 Sou, 2000, Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles, Bioconjug. Chem., 11, 372, 10.1021/bc990135y Uster, 1996, Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time, FEBS Lett., 386, 243, 10.1016/0014-5793(96)00452-8 Bogush, 1996, Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells, Anticancer Res., 16, 365 Bennis, 1997, Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin, Anticancer Drugs, 8, 610, 10.1097/00001813-199707000-00009 Deffie, 1988, Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and-resistant P388 leukemia, Cancer Res., 48, 3595 McPherson, 1997, Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha, Anticancer Res., 17, 4243 Abraham, 2002, Formation of transition metal-doxorubicin complexes inside liposomes, Biochim. Biophys. Acta, 1565, 41, 10.1016/S0005-2736(02)00507-2